novartis ag eu regulator approves once a year bone drug novartis ag said the european union approved its bone drug aclasta a treatment that needs to be taken only once a year switzerland based novartis said the eu regulator approved aclasta for the treatment of women with postmenopausal osteoporosis the drug was recently approved in the u s where it is sold under the brand name reclast aclasta is given as a minute infusion once a year 
